UNICREDIT BANK/CALL/ELI LILLY & CO/1100/0.1/18.09.24 | Real-time BOERSE MUENCHEN 10:42:14 06/06/2024 BST | ||
| 0.51 EUR | 0.00% |
|
| Current month | +13.33% | ||
| 1 month | +218.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 06/06/24 | 0.51 | 0.00% |
| 05/06/24 | 0.51 | -5.56% |
| 04/06/24 | 0.54 | 0.00% |
| 03/06/24 | 0.54 | +20.00% |
| 31/05/24 | 0.45 | +2.27% |
Real-time BOERSE MUENCHEN
Last update June 06, 2024 at 10:42 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD31WM |
| ISIN | DE000HD31WM8 |
| Date issued | 26/02/2024 |
| Strike | 1,100 $ |
| Maturity | 18/09/2024 (105 Days) |
| Parity | 10 : 1 |
| Emission price | 1.02 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.22 € |
|---|---|
| Lowest since issue | 0.077 € |
| Spread | 0.25 € |
| Spread % | 39.06% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
831.8
USD
Average target price
852.5
USD
Spread / Average Target
+2.50%
- Stock Market
- Warrants
- Warrant
